Profound Medical Corp. Common Stock PROF
$6.90
-0.14%
at last close
Analyst Consensus
- Consensus Rating
- Buy (1 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $12.00
- Implied Upside
- +73.9%
- Price Target Range
- $12.00 – $12.00
- Analysts (12 mo)
- 1
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-01-07 | Lake StreetBenjamin Haynor |
Maintains | Buy | $11 → $12 |
| 2025-04-23 | Lake StreetBenjamin Haynor |
Maintains | Buy | $17 → $11 |
| 2024-07-16 | StifelRick Wise |
Upgrades | Hold → Buy | $9 → $12 |
| 2024-03-11 | Alliance Global PartnersBen Haynor |
Maintains | Buy | $13 → $11 |
| 2024-03-08 | StifelRick Wise |
Maintains | Hold | $11 → $9 |
| 2024-01-04 | Alliance Global PartnersBen Haynor |
Maintains | Buy | $14 → $13 |
| 2023-11-28 | StifelRick Wise |
Initiates coverage on | Hold | $11 |
| 2023-08-04 | Raymond JamesRahul Sarugaser |
Downgrades | Strong buy → Outperform | — |
| 2023-05-11 | TD CowenJoshua Jennings |
Maintains | Outperform | $14 → $18 |
| 2023-05-11 | Alliance Global PartnersBen Haynor |
Maintains | Buy | $13 → $16 |
| 2023-03-21 | JefferiesMichael Sarcone |
Downgrades | Buy → Equal-weight | $6 → $10 |
| 2022-11-04 | Raymond JamesRahul Sarugaser |
Upgrades | Outperform → Strong buy | — |
| 2022-03-07 | Cowen & Co.Joshua Jennings |
Maintains | Outperform | $28 → $14 |
| 2022-02-22 | Raymond James |
Downgrades | Strong buy → Outperform | $28 → $23 |
| 2020-09-15 | JefferiesRaj Denhoy |
Initiates coverage on | Buy | — |
| 2020-09-10 | Lake Street |
Initiates coverage on | Buy | $22 |
| 2020-04-01 | Cowen & Co.Joshua Jennings |
Initiates coverage on | Outperform | $15 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $6.90
- Market Cap
- $252.49 million
- 52-Week Range
- $3.76 – $8.95
- Average Volume
- 237K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.